Quick Reference: Plasma Protein Products

Transcription

1 All plasma protein products a contraindicated in patients with any of the following: Hypersensitivity to the product or any ingdient in the formulation or component of the container. Pvious anaphylactic or seve systemic action to human immune globulin pparations. lga deficiency who have known antibody against lga. Warning: Plasma Protein a ppad from human plasma which may contain causative agents of blood-borne and viral diseases. Albumin Plasbumin 5 Plasbumin 25 Albumin 25% 50, 250 ml 100 ml 100 ml Emergent shock Burns Hypoproteinemia with or without edema Adult spiratory distss syndrome +2 to 30 C (all products) Risk of developing circulatory overload, especially in CHF, nal insufficiency, or chronic anemia. Albux 5 Albux , 500 ml 50 ml, 100 ml Acute liver failu Conditions such as acute peritonitis, pancatitis, mediastinitis, and extensive cellulitis Exchange transfusion May be used in acute nephrosis, nal dialysis, or cardiopulmonary bypass. Solvent/ detergent (S/D) tated Plasma Octaplasma 200mL Liquid Deficiencies of coagulation factors such as DIC Emergency substitution therapy in coagulation factor deficiency when pcise laboratory diagnosis is impeded by hemorrhage or when specific factor concentrate is not available. -18ºC (48 months) 4ºC for up to 8 hours ºC for up to 4 hours IgA deficiency with documented antibodies against IgA. Recipients with seve deficiencies of Protein S. Rapid versal of oral anticoagulants when not achievable by vitamin K, or

2 in hepatic impairment Tatment of: Primary immune deficiency Acquid immune deficiency Autoimmune disease Acute infections Allogeneic bone marrow transplantation Pediatric HIV infection Chronic inflammatory demyelinating polyneuropathy Idiopathic thrombocytopenic purpura B-cell chronic lymphocytic leukemia Temporary immunity following exposu to infection + 2 to 25 ºC Ra: Aseptic meningitis syndrome; Thrombotic events; Acute hemolytic actions; Intravascular hemolysis; Some products a associated with nal dysfunction, acute nal failu, and osmotic nephrosis. TRALI Do not administer to patients with seve thrombocytopenia, coagulation disorders. Intravenous Gammagard S/D Gamunex 10% 2.5g, 5g 2.5g, 5g, 10g, 20g Primary and secondary immune deficiency Efficacy in tatment of Guillian- Bar shown in clinical trials, if started within two weeks of symptoms. IGIVnex 10% 20g Octagam 10% Privigen 10% 5g, 10g, 20g 2.5g, 5g,10g, 20g, 40g

3 Subcutaneous Hizentra 20% 5, 10, 20 and 50 ml Primary and Secondary Immune Deficiency Contraindicated in patients with hyperprolinemia. HyperImmune Globulin Passive Immunity For all Hyperimmune Globulin: Risk of development of anaphylaxis in patients deficient in lga who may develop lga antibodies post tatment. Do not administer to patients with known immunity. Do not use in individuals with pvious allergic action to human immunoglobulin pparations. Hepatitis B HepaGamB 1 ml, 5 ml Tatment of acute exposu to blood containing hepatitis B surface antigen, including perinatal exposu Pvention of hepatitis B curnce following liver transplantation Varciella Zoster VariZIG 125 Pvention or duction in severity of maternal infection within four (4) days of exposu to the varicella zoster virus

4 Rh Immune Globulin Win RHo SDF units/mcg: 600/120, 1500/ / /120 m 1500/ / / ,000/3000 Pvention of RH immunization in Rho(D) negative mothers not pviously sensitized to the Rho(D) factor Immunization of Rho(D) negative women at risk of developing Rh antibodies Not to be administed to Rh (D) positive patients. Not to be administed to actively immunized patients.. Cytomegalovirus Cytogam 2500 ± 500 mg of Immunoglobulin Attenuation of primary Cytomegalourus disease in kidney transplant cipients who a seronegative for CMV and who ceive a kidney from a CMV seropositive donor. Recombinant Factor VIIa (rfviia) Niastase RT 1mg, 2mg, 5mg and 8mg vials Pvention and tatment of bleeding in patients with Hemophilia A with inhibitor to FVIII or Hemophilia B who have developed inhibitors to FIX. +2 to 30 ºC *Arterial and venous thromboembolic events. Factor VIII/vWF Humate P Anti-Hemophilic factor/ vonwillebrand Factor: / / , /1440 Pvention or tatment of bleeding in hemohphilia A and Von Willebrand Disease.

5 Wilate vwf/fviii:(with diluent) 500/500, 1000/1000 Hemophilia A (congenital or acquid Factor VIII deficiency) Tatment and prophylaxis of bleeding; Tatment and pvention of spontaneous trauma-induced bleeding in VWD and pediatric patients whe DDAVP is ineffective or contraindicated. Recombinant Factor VIII Concentrates Advate 250, 500, 1000, 1500, 2000, 3000,or 4000 units per vial. Hemophilia A - Control of bleeding Perioperative management Routine prophylaxis to pvent or duce the fquency of bleeding episodes. (all products) Serious Warning Factor VIII inhibitors may develop. Do not use in patients who a hypersensitive to mouse or hamster protein. Kogenate (Formulated with sucrose) 250, 500, 100, 200 or 300 Units per vial Hemophilia A - Control and pvention of hemorrhagic episodes Routine and surgical prophylaxis Xyntha - Recombinant Anti- Hemophilic Factor 250, 500, 1000, 2000 or 3000 units per vial Hemophilia A - Control and pvention of bleeding; routine surgical prophylaxis Factor IX Immunine VH Benefix 500 units 500, 1000, 2000, 3000 units Hemophilia B -Tatment and prophylaxis of bleeding episodes caused by congenital or acquid Factor IX deficiency Allergy to heparin; History of heparin induced thrombocytopenia; DIC and/or hyperfibrinolysis.

6 Factor XIII Corifact 250, 1250 Blood coagulation factor - Routine prophylaxis of bleeding Incased risk of thrombosis in patents with incased risk factors. Ttten (Recombinant) 2500 Prophylaxis of bleeding in patients with Factor XIIIA Subunit deficiency Prothrombin Complex Concentrates Octaplex 500 units/20ml Rapid versal of warfarin therapy or vitamin K deficiency in patients exhibiting major bleeding manifestations. Rapid versal of warfarin therapy or vitamin K deficiency in patients quiring urgent (within less than six hours) surgical procedus Heparin-induced thrombocytopenia Use only after termination of consumptive state in disseminated intravascular coagulation. Beriplex P/N 500 units/20 ml C1 Esterase Inhibitor Berinert 500 Tatment of acute attacks of heditary angioedema (HAE) of moderate to seve intensity. Antithrombin Antithrombin III NF , units/ml Prophylaxis and tatment of thrombotic and thromboembolic disorders in patients with heditary antithrombin deficiency. History of HIT.

7 Fibrinogen RiaSTAP 1g Tatment of congenital fibrinogen deficiency congenital afibrinogenemia, dysfibrinogenemia, and hypofibrinogenemia. Anti-inhibitor Anticoagulant Feiba NF units/20 ml Units/50mL Hemophilia A and B for: Control of spontaneous bleeding Surgical interventions Routine bleeding prophylaxis Risk of thrombosis when patients with congenital fibrinogen deficiency a tated with human fibrinogen concentrate, particularly with high dose or peated dosing. Thrombotic and thromboembolic events have been ported.